Table 4.
ZEB2 regulation by miRs in different cancers.
| MiR | Down-Stream Target | Cancer Type | Major Outcomes | Refs |
|---|---|---|---|---|
| MiR-29b | TET1/ZEB2 | Breast cancer | The miR-29b is an oncogene miR that inhibits TET1 to induce ZEB2 expression, leading to the EMT and colony formation of cancer cells | [336] |
| MiR-30a-5p | ZEB2 | Renal cancer | The miR-30a-5p reduces the expression of ZEB2 to be related with desirable prognosis of cancer cells | [337] |
| MiR-101 | ZEB2 | Osteosarcoma | Suppressing the invasion and proliferation of cancer cells through ZEB2 down-regulation | [175] |
| MiR-124 | ZEB2 | Triple negative breast cancer | MiR-124 diminishes the expression of ZEB2 to inhibit the EMT and invasion of cancer cells | [338] |
| MiR-129 | Wnt-β-catenin/ZEB2 | Non-small cell lung cancer | The miR-129 disrupts Wnt/ZEB2 axis to inhibit EMT | [339] |
| MiR-132 | ZEB2 | Colorectal cancer | Reducing the invasion and metastasis of cancer cells through ZEB2 down-regulation | [340] |
| Lung cancer | Diminishing the migration and invasion of cancer cells through ZEB2 inhibition | [341] | ||
| MiR-138 | ZEB2 | Bladder cancer | The miR-138 binds to the 3′-UTR of ZEB2 to inhibit the metastasis and invasion of cancer cells | [289] |
| MiR-141 | ZEB2 | Hepatocellular carcinoma | The miR-141 decreases the expression of ZEB2 to induce apoptosis and diminish viability and proliferation of cancer cells | [342] |
| Renal cancer | The administration of honokiol is associated with miR-141 induction and subsequent downregulation of ZEB2 to inhibit the malignancy of cancer cells | [343] | ||
| MiR-145 | ZEB2 | Non-small cell lung cancer | MiR-145 acts as an onco-suppressor miR that negatively affects the expression of ZEB2 to inhibit the progression and malignancy of cancer cells | [166] |
| Prostate cancer | There is a negative feedback loop between miR-145 and ZEB2, so that overexpression of miR-145 down-regulates the expression of ZEB2 to ensure the reduced viability and proliferation of cancer cells | [344] | ||
| MiR-145-5p | ZEB2 | Gastric cancer | The miR-145-5p decreases the levels of N-cadherin by ZEB2 down-regulation | [345] |
| MiR-153 | ZEB2 | Ovarian cancer | Acting as an onco-suppressor miR and reduces ZEB2 expression to EMT inhibition | [346] |
| MiR-154 | ZEB2 | Non-small cell lung cancer | The miR-154 exerts an anti-tumor impact by ZEB2 down-regulation | [347] |
| Hepatocellular carcinoma | The miR-154 functions as an onco-suppressor miR by inhibition ZEB2 expression and reducing cancer malignancy and proliferation | [348] | ||
| MiR-155 and FOXP3 | ZEB2 | Colorectal cancer | The miR-155 and FOXP3 inhibit ZEB2 expression to suppress EMT via E-cadherin level up-regulation and Vimentin level downregulation | [307] |
| MiR-187 | ZEB2 | Osteosarcoma | The miR-187 decreases the expression of ZEB2 to inhibit the malignancy and migration of tumor cells | [349] |
| MiR-200 | ZEB1/2 | Ovarian cancer | The cancer cells acquire an epithelial phenotype by enhancing the expression of miR-200 and subsequent inhibition of ZEB1 and ZEB2 proteins | [350] |
| ZEB2 | Breast cancer | As an onco-suppressor miR, miR-200 decreases the expression of ZEB2 and its targets gene Snail1 to induce mesenchymal to epithelial transition | [351] | |
| MiR-200a | ZEB2 | Nasopharyngeal carcinoma | Suppressing the growth and invasion of cancer cells through ZEB2 down-regulation | [352] |
| Hepatocellular carcinoma | The miR-200a diminishes the expression of ZEB2 to suppress EMT and invasion of cancer cells | [353] | ||
| Ovarian cancer | The miR-200a increases the levels of E-cadherin by EMT inhibition and ZEB2 down-regulation | [354] | ||
| MiR-200b | ZEB2 | Gastric carcinoma | Inhibition of ZEB2 by miR-200b suppresses invasion, metastasis, and migration of cancer cells | [355] |
| Glioma | Reducing the growth and metastasis of ZEB2 inhibition | [356] | ||
| MiR-200c | ZEB2 | Ovarian cancer | MiR-200c reduces the expression of ZEB2 to inhibit EMT by enhancing E-cadherin levels and reducing Vimentin levels | [357] |
| Non-small cell lung cancer | The miR-200c inhibits EMT mechanism by ZEB2 down-regulation | [358] | ||
| MiR-200c-3p | ZEB2 | Prostate carcinoma | The miR-200c-3p functions as an anti-tumor miR that inhibits the progression and invasion of cancer cells through ZEB2 down-regulation | [359] |
| MiR-203 | ZEB2 | Lung adenocarcinoma and nasopharyngeal carcinoma | MiR-203 enhances the efficacy of cisplatin in chemotherapy and eradication of cancer cells, and also inhibits their invasion by EMT down-regulation through ZEB2 inhibition | [360,361] |
| MiR-205 | ZEB2 | Renal cell carcinoma | The miR-205 is related to the favorable prognosis and reduced invasion of cancer cells through ZEB2 down-regulation | [362] |
| MiR-206 | ZEB2 | Renal cancer | Decreasing the proliferation of tumor cells through ZEB2 down-regulation | [363] |
| MiR-211-5p | ZEB2 | Hepatocellular carcinoma | The miR-211-5p suppresses the metastasis of cancer cells via ZEB2 down-regulation | [215] |
| MiR-215 | ZEB2 | Non-small cell lung cancer | The in vitro and in vivo experiments demonstrate the potential of miR-215 in down-regulation of ZEB2 and suppressing the invasion, progression, and malignancy of cancer cells, and induction of apoptotic cell death | [364] |
| MiR-335 | ZEB2 | Colorectal cancer | The inhibition of metastasis and invasion of cancer cells through ZEB2 down-regulation | [365] |
| Papillary thyroid cancer | Through reducing the expression of ZEB2, miR-335 suppresses the growth and metastasis of cancer cells | [366] | ||
| MiR-338-3p | ZEB2 | Gastric cancer | MiR-338-3p diminishes the expression of ZEB2 to inhibit EMT in cancer cells | [367] |
| MiR-454-3p and miR-374b-5p | ZEB2 | Bladder cancer | Reducing the expression of ZEB2 significantly decreases the migration and invasion of cancer cells | [325] |
| MiR-506 | ZEB2 | Gastric carcinoma | The miR-506 suppresses metastasis through ZEB2 down-regulation | [130] |
| MiR-545 | Wnt-β-catenin/ZEB2 | Non-small cell lung cancer | The miR-545 reduces the expression of Wnt/β−catenin to down-regulate the expression of ZEB2, leading to the decreased migration and invasion of cancer cells | [368] |
| MiR-598 | ZEB2 | Non-small cell lung cancer | The in vitro experiment demonstrated that miR-598 decreases the expression of ZEB2 to inhibit the migration and metastasis of cancer cells | [369] |
| MiR-622 | ZEB2 | Glioma | The increased expression of miR-622 is related to the desirable prognosis via ZEB2 down-regulation | [370] |
| MiR-769-3p | Wnt-β-catenin/ZEB2 | Glioma | The miR-769-3p down-regulates the expression of Wnt and inhibits nuclear translocation of β−catenin to suppress ZEB2, leading to the decreased viability, proliferation and invasion of cancer cells | [371] |
| MiR-940 | ZEB2 | Glioma | Inhibition of cancer progression and EMT through ZEB2 down-regulation | [372] |
| MiR-1179 | ZEB2 | Hepatocellular carcinoma | The miR-1179 reduces the expression of ZEB2 to inhibit cancer progression and malignancy | [373] |
| MiR-3653 | ZEB2 | Colon cancer | Suppressing metastasis and EMT by inhibition of ZEB2 | [171] |